At 3.2x earnings and 0.8x book, the market is pricing CSHR like a distressed asset, not a functioning capital markets platform generating a 27.70% operating margin and 25.10% ROIC. The negative EPS of -8.5 against an estimated $1.71 next year implies a violent earnings swing, yet the absence of a Forward P/E and a catastrophic Altman Z-Score of 0.4 signal real balance sheet fragility. This is a classic deep value paradox: statistically cheap on trailing multiples, but carrying genuine solvency risk. The market is not obviously wrong — it is discounting heavy financial risk — but if the earnings normalization materializes, the 3.2 P/E could prove absurdly low.